Allogeneic HSCT For Pediatric Extranodal NK/T-Cell Lymphoma Transformed From Chronic Active Epstein-Barr Virus Infection: A Case Report.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
This study aimed to explore the clinical characteristics, diagnostic criteria, therapeutic regimens, and prognostic features of pediatric extranodal natural killer/T-cell lymphoma (ENKTL) transformed from chronic active Epstein-Barr virus infection (CAEBV), to provide evidence-based references for standardized clinical diagnosis and treatment of these refractory diseases. A pediatric patient with CAEBV-transformed ENKTL admitted to Nanshan Hospital Affiliated to Shenzhen University was retrospectively enrolled in this study, who received allogeneic hematopoietic stem cell transplantation (allo-HSCT). The patient achieved complete remission after multiple cycles of preoperative chemotherapy. Triple probiotic preparations containing Bifidobacterium, Bacillus licheniformis, and Lactobacillus were administered throughout the preconditioning phase and post-transplant period. Persistent complete remission was achieved after transplantation with full donor chimerism of 100%. Long-term follow-up over 1 year post-transplantation showed no disease recurrence, EBV reactivation, severe infectious complications, or acute and chronic transplantation-related complications. This case study confirmed that allo-HSCT is safe and effective for the treatment of pediatric CAEBV-transformed ENKTL, with a significantly superior long-term prognosis compared with chemotherapy alone. Peri-transplant adjuvant application of microecological preparations may reduce the risks of respiratory tract infection and graft-versus-host disease in children. Given that this is a single-case study with limited follow-up duration, there are certain limitations in the clinical generalization of the conclusions.